PHP
PVLA

Parkman Healthcare Partners’s Palvella Therapeutics PVLA Stock Holding History

Parkman Healthcare Partners’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,736
Closed -$1.42M – 94
2020
Q2 		$1.42M Sell
5,736
-500
-8% -$117K 0.4% 63
2020
Q1 		$1.14M Sell
6,236
-1,533
-20% -$386K 0.53% 51
2019
Q4 		$2.25M Buy
+7,769
New +$2.15M 0.65% 47

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Parkman Healthcare Partners's PVLA Position: Q3 2020 in Review

Parkman Healthcare Partners sold out of Palvella Therapeutics (PVLA) in Q3 2020, closing a stake of 5,736 shares — an estimated $1.42M sold.

Parkman Healthcare Partners first reported a position in PVLA in Q4 2019 and held it in 3 quarters. The position peaked at $2.25M in Q4 2019. 88 funds tracked by Wall St. Rank hold PVLA as of Q3 2020.

  • Parkman Healthcare Partners reported no remaining Palvella Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Parkman Healthcare Partners sold 5,736 Palvella Therapeutics shares in Q3 2020, an estimated $1.42M.
  • Parkman Healthcare Partners first reported a position in Palvella Therapeutics in Q4 2019 and held it in 3 quarters.
  • Parkman Healthcare Partners's Palvella Therapeutics position peaked at $2.25M in Q4 2019.
  • 88 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2020.

Based on Parkman Healthcare Partners's 13F filing for Q3 2020, filed 13 Nov 2020.